Participants for whom data was available were more likely to be White, have a mother with more than a high school education, have private insurance, live in non-urban environment, have married parents, have an older mother, have a higher income, have reportedly less prenatal tobacco exposure, and have lower maternal mean prenatal cotinine ().
| Table ICharacteristics and Exposures of Study Participants |
Twelve percent of mothers reported active exposure, and 26% reported active or passive exposure (). Cotinine was detectible in 68.6% of 16 week maternal serum samples and in over half of the samples at other prenatal time points (). Cotinine was detectible in an even higher percentage of child serum samples; the mean serum cotinine concentrations were higher in child than maternal serum cotinine (). Cotinine concentrations in serum and meconium were significantly correlated, (Pearson’s r=0.49 to 0.94, ). Prenatal maternal serum cotinine at each time point was more closely correlated with the other prenatal serum cotinine and meconium biomarkers than with reported exposure.
| Table IITobacco Exposure levels of the Study Participants |
| Table IIICorrelation of Tobacco Exposure Measures: Cotinine and Reported Exposure |
By age two, 44.9% of children had wheezed at least once. In the first six month period 18.5% of the children had at least one reported wheeze episode, in the second six month period (age six to twelve months) 22.3% had at least one wheeze episode, in the third six month period (age twelve to eighteen months) 19.3% had at least one wheeze episode, and in the fourth six month period (age eighteen to twenty-four months) 15.3% had at least one wheeze episode. The mean number of wheeze episodes was 0.5 from birth to six months, 0.7 from six months to 12 months, 0.5 from 12 months to 18 months, and 0.6 from 18 months to 24 months of age.
In bivariate analysis of tobacco exposure, there was an association of 16 week maternal serum cotinine, 26 week maternal serum cotinine, birth maternal serum cotinine, mean maternal serum cotinine, reported active prenatal smoke exposure, and reported total (active plus passive) tobacco exposure with wheeze (). There was no association of cord serum cotinine, meconium cotinine, or child serum cotinine with wheeze (). When the two variables, reported active exposure and reported passive exposure, were included in the same analysis there was no association of either with wheeze.
| Table IVUnadjusted and Adjusted Associations of Tobacco Exposure with Wheeze |
In bivariate analysis of potential covariates, there was an association of maternal allergy, maternal asthma, home density (house volume/ child), and season with wheeze. There was no association of sex, maternal race, gestational age, breastfeeding duration, reported cat exposure, reported dog exposure, reported cockroach exposure, reported paternal allergy, reported paternal asthma, reported child allergy, or daycare exposure with wheeze.
In multivariable analysis, we found a 2.6 fold increase in odds of wheeze for children born to mothers in the 95th percentile of mean prenatal maternal serum cotinine compared with children born to mothers in the 5th percentile (AOR=2.61, 95% CI 1.31 – 5.19, p<0.006, ) and a 2.0 fold increase in odds of wheeze for children born to mothers in the 95th percentile of meconium cotinine compared with children born to mothers in the 5th percentile (AOR 2.04, 95% CI 1.03 – 4.06, p=0.04). We analyzed reported prenatal tobacco exposure in three separate ways. First, we found a 2.0 fold increase in odds of wheeze for children born to mothers in the 95th percentile of reported active exposure compared with children born to mothers in the 5th percentile (AOR=2.0, 95% CI 1.18 – 3.4, p=0.01). Second, for the sum of reported active maternal tobacco smoking and reported passive (other household members) tobacco smoking we found a 1.7 fold increase in odds of wheeze for children born to mothers in the 95th percentile of reported total exposure compared with children born to mothers in the 5th percentile (AOR=1.73, 95% CI 1.13 – 2.66, p=0.01). Third, we evaluated reported active and passive exposure as separate variables with equal weight in the same analysis and found that the associations were attenuated (reported active smoking p=0.07 and reported passive tobacco smoking p=0.34). We did not find any significant interactions for cotinine with maternal race or season.
In secondary analysis, we examined timing of exposure by using the maternal serum cotinine level measured at different times during pregnancy. In the adjusted analysis of 16 week maternal serum cotinine, we found a 2.8 fold increase in odds of wheeze for children born to mothers in the 95th percentile of reported total exposure compared with children born to mothers in the 5th percentile (AOR=2.83, 95% CI 1.31 – 6.14, p=0.009). The findings were similar for the analysis of 26 week maternal serum cotinine (AOR=2.65, 95% CI 1.30 – 5.39, p=0.008) and birth maternal serum cotinine (AOR=2.52, 95% CI 1.15 – 5.52, p=0.02).
In other secondary analyses we examined the association of childhood exposure with wheeze. In a multivariable analysis without prenatal tobacco exposure, we found that postnatal child serum cotinine was not associated with wheeze. We found a 1.6 fold increase in odds of wheeze for children in the 95th percentile of serum cotinine compared with children in the 5th percentile (AOR=1.58, 95% CI 0.77 – 3.24, p=0.21).